Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11634423 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling

Patent 11634423 was granted and assigned to Eli Lilly and Company on April, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Eli Lilly

Current Assignee

Eli Lilly

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

116344230

Patent Inventor Names

Thomas John Bleisch0

Zhaogen Chen0

Theodore Curtis Jessop0

Date of Patent

April 25, 2023

Patent Application Number

171683990

Date Filed

February 5, 2021

Patent Citations

‌

US Patent 10273237 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses

Patent Citations Received

‌

US Patent 12060356 7 (methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives

‌

US Patent 11891400 Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11634423 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API